Vortioxetine as adjunctive therapy in the treatment of schizophrenia

Journal article


Redaelli, Sofia, Porffy, Lilla, Oloyede, Ebenezer, Dzahini, O., Lewis, Gabriella, Lobo, Maria, Whiskey, E. and Shergill, Sukhi S. 2022. Vortioxetine as adjunctive therapy in the treatment of schizophrenia. Therapeutic Advances in Psychopharmacology. 12, p. 204512532211100. https://doi.org/10.1177/20451253221110014
AuthorsRedaelli, Sofia, Porffy, Lilla, Oloyede, Ebenezer, Dzahini, O., Lewis, Gabriella, Lobo, Maria, Whiskey, E. and Shergill, Sukhi S.
AbstractBackground: The evidence for safe and effective interventions to treat the negative and cognitive symptoms of schizophrenia is lacking. Objectives: Vortioxetine is a novel antidepressant that has been used as adjunctive therapy for the treatment of psychosis; however, its effectiveness in clinical practice is relatively unknown. In this study, we aimed to determine the potential clinical effectiveness and safety and tolerability of vortioxetine in psychosis. Design: This is a non-interventional, retrospective study on the add-on use of vortioxetine in a group of people with schizophrenia-spectrum disorders in a large UK NHS mental health trust. Methods: Clinical effectiveness of vortioxetine was retrospectively assessed through the Clinical Global Impression – Severity (CGI-S) scale at 3 months. Safety and tolerability were evaluated through treatment discontinuation rates at 3, 6, and 12 months, and clinical reasons were evaluated at the primary endpoint of 3 months. Results: Data were available for 40 subjects with a diagnosis of schizophrenia or schizoaffective disorder–prescribed vortioxetine treatment; 30 (75%) remained on treatment at 3 months. At CGI-S assessment, 15 of the 35 evaluated subjects reported at least a 1-point improvement, from 5 at baseline to 4 after 3 months of treatment. Twenty-six (65%) remained on treatment at 1-year follow-up. The main reasons for those discontinuing treatment were inadequate response (10%) and manic switch (7.5%), while one subject refused treatment. Tolerability to treatment was good, and 36 subjects (90%) reported no adverse events specific to vortioxetine treatment. Conclusion: Schizophrenia is a complex illness, and there is insufficient treatment response in many individuals. A significant proportion of whom may require adjunctive treatments depending on the nature of the residual symptoms. Vortioxetine could be a potentially safe and effective option in such people, but further controlled studies are required.
KeywordsVortioxetine ; Schizophrenia; Treatment
Year2022
JournalTherapeutic Advances in Psychopharmacology
Journal citation12, p. 204512532211100
PublisherSAGE Publications
ISSN2045-1253
2045-1261
Digital Object Identifier (DOI)https://doi.org/10.1177/20451253221110014
Official URLhttps://journals.sagepub.com/doi/full/10.1177/20451253221110014
FunderKing's College London
Publication dates
Online05 Jul 2022
Publication process dates
Accepted08 Jun 2022
Deposited18 Jul 2022
Publisher's version
License
Output statusPublished
Permalink -

https://repository.canterbury.ac.uk/item/9180q/vortioxetine-as-adjunctive-therapy-in-the-treatment-of-schizophrenia

Download files


Publisher's version
20451253221110014.pdf
License: CC BY-NC 4.0

  • 13
    total views
  • 2
    total downloads
  • 3
    views this month
  • 0
    downloads this month

Export as

Related outputs

Cognitive bias modification for paranoia (CBM-pa): a randomised controlled feasibility study in patients with distressing paranoid beliefs.
Yiend, Jenny, Lam, C., Schmidt, Nora, Crane, Bryony, Heslin, Margaret, Kabir, Thomas, McGuire, Philip, Meek, Christopher, Mouchlianitis, Elias, Peters, Emmanuelle, Stahl, Daniel, Trotta, Antonella and Shergill, Sukhwinder 2022. Cognitive bias modification for paranoia (CBM-pa): a randomised controlled feasibility study in patients with distressing paranoid beliefs. Psychological Medicine. https://doi.org/10.1017/S0033291722001520
The role of cognitive control in the positive symptoms of psychosis
Horne, Charlotte M., Sahni, Angad, Pang, Sze W., Vanes, Lucy D., Szentgyorgyi, Timea, Averbeck, Bruno, Moran, Rosalyn J. and Shergill, Sukhwinder S. 2022. The role of cognitive control in the positive symptoms of psychosis. NeuroImage. Clinical. 34, p. 103004. https://doi.org/S2213-1582(22)00069-9
Direct eye gaze enhances the ventriloquism effect
Lavan, N., Chan, Wing Yue, Zhuang, Yongping, Mareschal, Isabelle and Shergill, Sukhwinder S. 2022. Direct eye gaze enhances the ventriloquism effect. Attention, Perception & Psychophysics. https://doi.org/10.3758/s13414-022-02468-5
New approaches to antipsychotic medication adherence – safety, tolerability and acceptability
Taub, Sharon, Krivoy, Amir, Whiskey, Eromona and Shergill, Sukhi S. 2021. New approaches to antipsychotic medication adherence – safety, tolerability and acceptability. Expert Opinion on Drug Safety. 21 (4), pp. 517-524. https://doi.org/10.1080/14740338.2021.1983540
A systematic review of TMS and neurophysiological biometrics in patients with schizophrenia
di Hou, Meng, Santoro, Viviana, Biondi, Andrea, Shergill, Sukhi S and Premoli, Isabella 2021. A systematic review of TMS and neurophysiological biometrics in patients with schizophrenia. Journal of psychiatry & neuroscience : JPN. 46 (6), pp. E675-E701. https://doi.org/10.1503/jpn.210006